Affimed NV (NASDAQ:AFMD) – Equities researchers at Jefferies Financial Group decreased their FY2019 earnings estimates for Affimed in a research report issued to clients and investors on Tuesday, November 19th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of ($0.61) per share for the year, down from their prior forecast of $0.29. Jefferies Financial Group also issued estimates for Affimed’s Q4 2019 earnings at ($0.25) EPS, FY2020 earnings at ($0.34) EPS, FY2021 earnings at $0.07 EPS, FY2022 earnings at $1.14 EPS and FY2023 earnings at ($0.73) EPS.
A number of other equities research analysts also recently weighed in on the stock. ValuEngine upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Zacks Investment Research downgraded shares of Affimed from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $6.36.
Affimed (NASDAQ:AFMD) last released its quarterly earnings results on Tuesday, November 19th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). Affimed had a negative net margin of 25.43% and a negative return on equity of 26.26%. The business had revenue of $2.34 million during the quarter, compared to analyst estimates of $6.77 million.
Large investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board bought a new position in Affimed in the second quarter valued at approximately $574,000. Acadian Asset Management LLC grew its stake in shares of Affimed by 3,524.2% during the second quarter. Acadian Asset Management LLC now owns 2,176,604 shares of the biopharmaceutical company’s stock worth $6,247,000 after buying an additional 2,116,546 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Affimed during the second quarter worth $8,399,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Affimed during the second quarter worth $360,000. Finally, Meeder Asset Management Inc. bought a new stake in shares of Affimed during the third quarter worth $47,000. 47.93% of the stock is currently owned by institutional investors and hedge funds.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Story: What is diluted earnings per share (Diluted EPS)?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.